Expert Pancreatic Cancer Surgery in Shanghai
Access world-class hepatobiliary-pancreatic care at Shanghai's leading university hospitals. Performed by surgeons who do 2,000+ of these procedures a year — at a fraction of the cost.
Read Our Patient GuidesThe Data Behind Shanghai's Hepatobiliary-Pancreatic Excellence
Shanghai's top hospitals perform pancreatic and hepatobiliary surgery at volumes that rival or exceed Memorial Sloan Kettering, Johns Hopkins, and the Royal Marsden.
World-Class Surgical Volume
Pancreatic cancer has a 5-year survival rate of just 12%. But for the 20% of patients who are surgical candidates, the choice of where to have surgery is the most important decision they'll make.
The volume-outcome relationship in pancreatic surgery is one of the strongest in all of surgery. Shanghai's Ruijin Hospital performs 2,000+ pancreatic surgeries per year — and Fudan Cancer Center performs 3,000+ complex oncology surgeries. These are numbers many Western surgeons never reach in their entire careers.
Five Premier Hospitals
Ruijin Hospital
瑞金医院
2,000+ pancreatic surgeries/year. Robotic Whipple pioneer. International patient coordinators.
Fudan University Shanghai Cancer Center
复旦大学附属肿瘤医院
3,000+ complex oncology surgeries/year. 80%+ minimally invasive rate. Clinical trials hub. 72% 5-year survival.
Huashan Hospital
华山医院
Fudan University affiliated. Strong general surgery with pancreatic expertise. International patient ward.
Changhai Hospital
长海医院
Naval Medical University. High-volume hepatobiliary-pancreatic surgery. Military-affiliated with civilian access.
Advanced Surgical Technology
Shanghai's top hospitals are equipped with the same technology found at major Western cancer centers.
Significantly Lower Cost, Same Quality
The same Whipple procedure, performed by surgeons with higher case volumes, for a fraction of the price. Plus, 30-day visa-free entry for 47+ countries.
| USA | UK (NHS) | UK (Private) | Australia | Shanghai | |
|---|---|---|---|---|---|
| Whipple Procedure | $150K–$250K | Free | £30K–£60K | AUD $50K–$100K | $11K–$28K |
| Wait Time | 4–8 weeks | 3–6 months | 2–4 weeks | 4–8 weeks | 2–4 weeks |
| Liver Surgery | $100K–$200K | Free (wait 2–4 mo) | — | — | $8K–$22K |
| Quality | World-class | World-class | Good | Good | World-class |
30-Day Visa-Free Entry
Citizens of the US, UK, Canada, Australia, NZ, and most EU countries can fly to Shanghai — no visa application, no embassy visit. Stay up to 30 days.
See the full cost breakdown →Your Journey to Treatment
From first contact to flying home — a clear, guided process.
Gather Records
CT/MRI images, pathology report, blood work
Remote Consult
Video call with the surgical team. Preliminary opinion & cost estimate.
Book & Fly
30-day visa-free. Coordinator meets you at the airport.
Surgery & Recovery
Pre-op workup in 2 days. Surgery. 2–3 week recovery.
Fly Home
English discharge summary. Remote follow-up with your local oncologist.
In-Depth Resources
Data-driven guides and real patient experiences.
Alibaba's DAMO PANDA: First AI Model to Receive FDA 'Breakthrough Device' Status for Pancreatic Cancer Screening
Alibaba DAMO Academy's AI model can detect pancreatic cancer from routine CT scans with 92.9% sensitivity and 99.9% specificity — years before symptoms appear. Now FDA-recognized as a breakthrough medical device.
A Brazilian Doctor Told Him: 'Go to Shanghai — That's Where the Best Surgeons Are'
How a Chinese-Brazilian patient flew 20,000 km from São Paulo to Ruijin Hospital for a robotic Whipple procedure — and why his Brazilian surgeon recommended it.
China's Global Leadership in Pancreatic Cancer: A 2024-2026 Deep Dive
From heavy ion therapy to robotic surgery to KRAS inhibitors — how China went from follower to leader in pancreatic cancer treatment. A comprehensive report on breakthroughs, survival rates, and next-generation drugs.
Pancreatic Cancer Therapeutic Vaccines: Evidence Review of 7 Projects (2026)
Deep evidence grading of 7 pancreatic cancer vaccine projects — Neo-P DC, WT1 DC, PCNAT-01, P01, LK101, XH001, RGL-270. What the data actually shows vs. what's marketing.
From Follower to Leader: Ruijin Hospital Achieves 21.2% Five-Year Survival in Pancreatic Cancer
How Ruijin Hospital's Pancreatic Disease Center became a global benchmark — 30,000+ cases treated, 21.2% 5-year survival (vs 9-12% global average), 4,000+ robotic surgeries, and China's first voice in the ESMO Asia-Pacific Consensus.
Pancreatic Cancer Surgery in Shanghai: What International Patients Need to Know
A disease-focused guide to hepatobiliary-pancreatic oncology in Shanghai — hospitals, surgeons, techniques, and what the data actually says.
UK Patient Waited 6 Months — Flew to Shanghai, Had Surgery in 2 Weeks
How China's visa-free policy is opening a door for pancreatic cancer patients who can't afford to wait — or to pay.
China's 30-Day Visa-Free Policy Made Pancreatic Cancer Surgery Abroad Feasible
A realistic breakdown of costs, wait times, and logistics for patients considering hepatobiliary-pancreatic surgery in Shanghai.